Devising a personalized risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes

DORIAN GRAY project investigates the link between cardiovascular disease (CVD) and Mild Cognitive Impairment (MCI) in the ageing population. Its goal is to uncover underlying mechanisms to promote healthy, independent, and active living while reducing disease burden. Aligned with EU-Horizon Europe’s Strategic Plan on NCDs prevention, the project focuses on two core objectives: designing a multidomain intervention to delay CVD-related MCI progression and developing digital solutions to enhance its adherence.By leveraging large datasets that include omics, brain imaging, lifestyle behaviors, and socio-economic data, the project aims to develop a trustworthy AI tool for predicting MCI. The AI tool will be upgraded into a state-of-the-art framework for modelling and simulation (digital twin), integrating real-world data collected in clinical studies from smartwatches and mobile devices. Including these digital biomarkers enable the early detection of disease and enhance precision in healthcare.The DIGITAL TWIN will inform and update a personalized multidomain intervention using a novel avatar-based coaching exergame, which will serve dual purposes: as a cognitive enhancement tool with structured physical-cognitive tasks and as a lifestyle intervention promoting positive behaviours experienced in the virtual environment. Feasibility will be tested in a pilot randomized controlled trials involving patients with MCI and heart failure, and in an implementation study with patients having MCI and cardiovascular risk factors.To achieve his aim DORIAN GRAY brings together a diverse team of experts, including clinicians, psychologists, sports scientists, computers engineers, AI specialists, stakeholders, entrepreneurs, and academics in ethics, law, and theoretical philosophy. Patients and citizens actively engage in shaping and guiding project decisions. DORIAN GRAY is projected to prevent up to 2 million dementia cases over 27 years, leading to a cost reduction of 485 billion.